RVPH · Reviva Pharmaceuticals Holdings, Inc.
$0.39
+0.04 (+10.76%)
At close · May 14
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued. ... These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$6.33M
Shares
13.11M
Volume · May 14
742.02K
Avg daily vol (48 sessions)
985.8K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.39
Open$0.36
Day$0.31–0.39
52W close$0.35–22.40
Avg vol 30d925K
Short int409K · 3.1% float · 3.4d
Short vol42%
DataDec 2020–May 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$13.02M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$19.75M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−94%
below
Price vs 50-day avg
−68%
below
RSI (14)
22
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−55%
trailing
6-month return
−96%
trailing
YTD return
−93%
this year
Relative strength
−109%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $7 — 200d above 50d
Institutional flow
Flat
1 of 5 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.12% of float · ▼ -4.2% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
166%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
34.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−94%
Bearish
Price vs 50-day avg
−68%
Bearish
RSI (14)
22
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $7 — 200d above 50d
Institutional flow
Flat
1 of 5 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.12% of float · ▼ -4.2% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $22
vs 200-day avg -94%
vs 50-day avg -68%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVPH
this stock
Reviva Pharmaceuticals Holdings, Inc.
|
$6.33M | — | — | — | 3.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVPH | -54.8% | -55.4% | -96.1% | -55.2% | -93.0% |
| SPY | +2.3% | +6.6% | +12.9% | +4.1% | +9.7% |
| vs SPY | -57.1% | -62.0% | -109.0% | -59.3% | -102.7% |